With a therapeutic space that is rapidly evolving and requires multidisciplinary management to optimize care, cutaneous squamous cell carcinoma (CSCC) necessitates that clinicians to stay up to date on recent approvals, clinical trial data, and guideline recommendations. This Phone-a-Friend series will invite experts in the field to discuss typical patient case scenarios and real-world topics such as the identification of patients with metastatic disease who may be candidates for immunotherapy, monitoring and managing adverse events following treatment with immune checkpoint inhibitors, understanding which patients have a high risk of disease recurrence, and the roles that adjuvant and neoadjuvant immunotherapy can play in patients’ treatment regimens.